PBM Reform Nears: Congress, Labor Dept. Target Pharmacy Benefit Managers with Fiduciary Rules

After years of complaints from patients, pharmacies, and employers, Washington is finally moving to fundamentally reform Pharmacy Benefit Managers (PBMs). The core of the coming change is a push to make PBMs legally accountable as fiduciaries, aligning their financial incentives with the employers and patients they serve, rather than allowing them to profit as opaque middlemen. This shift, driven by both Congress and the Department of Labor, represents the most significant regulatory threat to the PBM industry's traditional business model in decades.

Research underscores why this crackdown is gaining momentum. Studies, including work from the USC Schaeffer Center, reveal that PBM negotiations often fail to generate savings for payers. A stark example: between 2014 and 2018, PBMs' share of insulin expenditures nearly tripled, yet overall costs for payers did not drop. The system creates perverse incentives where higher drug rebates, negotiated by PBMs, correlate directly with higher drug list prices—approximately $1.17 increase for every additional rebate dollar. This dynamic directly inflates out-of-pocket costs for patients whose co-pays are based on those inflated list prices.

The impending fiduciary standard aims to dismantle this conflict of interest. If implemented, it would legally compel PBMs to act in the best financial interest of their plan sponsor clients, potentially curbing practices that have long drawn scrutiny from consumer groups and independent pharmacies. The reform signals a profound shift in oversight for a powerful but often-criticized link in the U.S. pharmaceutical supply chain, placing it under a new regime of accountability.